COMPANY PROFILE

Addition Therapeutics

Explore full profile

Developing of RNA-based genetic medicines using a non-viral insertion platform for chronic and rare diseases

South San Francisco, United StatesFounded 2021Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2021
Headquarters: South San Francisco, United States
Employees: 65
Open positions: 4
Dealroom signal: 83.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Genetics and genomics, Chronic Disease, Gene Therapy, Spinout, Genome Engineering, Biotech and Pharma, Rare Diseases, Woman Founder, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Dec 2025	$100M	$400M	SR One · Osage University Partners · Abingworth · Bill & Melinda Gates Foundation	↗
SUPPORT PROGRAMOther financing	Jul 2021	$0	—	Bakar Bio Labs	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Addition Therapeutics website traffic

Latest recorded traffic for Addition Therapeutics is 2.1K monthly website visits, down 44.7% over the last three months. Addition Therapeutics's team grew 1.6% over the past year.

Latest monthly visits2.1K 3-month web change-44.7% 1-year team growth+1.6%

Monthly website visitsAug 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MTMuna TherapeuticsDiscovering and developing transformative therapeutics for neurodegenerative diseases	Copenhagen, Denmark	Operational	59	$79M	$292M
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
OBOctarine BioHarnessing the powers of synthetic biology to develop rare and superior cannabinoids and psychedelic derivatives	Copenhagen, Denmark	Operational
BIBioSkrybBioSkryb is a developer of genomic amplification technologies that deliver unprecedented coverage for various gene sequencing applications	Durham, United States	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational
OGOryzon GenomicsDevelops diagnostic and therapeutic tools	Cornellà de Llobregat, Spain	Operational
HGHeart GeneticsGenetics and Biotechnology	Cantanhede, Portugal	Operational
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational